Abstract
The effects of zileuton, a new 5-lipoxygenase inhibitor, on leukotriene generation and clinical response in rheumatoid arthritis (RA) was studied in a 4-week randomized double blind placebo controlled study at 2 academic rheumatology centers. Zileuton decreased the mean (+/- SEM) ionophore induced synthesis of leukotriene B4 at Week 1 by 70% from 191.2 +/- 28.5 to 57.5 +/- 17.0 ng/ml. A parallel suppression of all major 5-lipoxygenase pathway products was observed. An improvement in clinical variables was observed in the zileuton and placebo treated population. No unique toxicity was identified in this study. Zileuton inhibited 5-lipoxygenase in RA with a suggestion of clinical response with limited toxicity.
Publication types
-
Clinical Trial
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Aged
-
Anti-Inflammatory Agents, Non-Steroidal / adverse effects
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
-
Arthritis, Rheumatoid / drug therapy*
-
Arthritis, Rheumatoid / enzymology
-
Arthritis, Rheumatoid / metabolism
-
Double-Blind Method
-
Female
-
Humans
-
Hydroxyurea / adverse effects
-
Hydroxyurea / analogs & derivatives*
-
Hydroxyurea / therapeutic use
-
Leukotriene B4 / metabolism
-
Lipoxygenase Inhibitors* / adverse effects
-
Lipoxygenase Inhibitors* / therapeutic use*
-
Male
-
Middle Aged
-
Time Factors
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Lipoxygenase Inhibitors
-
Leukotriene B4
-
zileuton
-
Hydroxyurea